IRIS
LAPUCCI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.055
AS - Asia 880
NA - Nord America 650
SA - Sud America 69
AF - Africa 12
OC - Oceania 3
Totale 6.669
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.924
US - Stati Uniti d'America 614
SG - Singapore 351
CN - Cina 229
VN - Vietnam 187
BR - Brasile 45
FR - Francia 43
HK - Hong Kong 27
BD - Bangladesh 23
CA - Canada 19
DE - Germania 19
GB - Regno Unito 13
AR - Argentina 11
IN - India 11
MX - Messico 11
FI - Finlandia 10
IQ - Iraq 9
PK - Pakistan 9
JP - Giappone 8
NL - Olanda 8
CH - Svizzera 7
AZ - Azerbaigian 5
RU - Federazione Russa 5
SA - Arabia Saudita 5
EC - Ecuador 4
ES - Italia 4
PH - Filippine 4
IE - Irlanda 3
PL - Polonia 3
UA - Ucraina 3
ZA - Sudafrica 3
AU - Australia 2
CL - Cile 2
HR - Croazia 2
ID - Indonesia 2
JM - Giamaica 2
JO - Giordania 2
KE - Kenya 2
KZ - Kazakistan 2
LT - Lituania 2
MA - Marocco 2
PY - Paraguay 2
TN - Tunisia 2
UZ - Uzbekistan 2
VE - Venezuela 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BY - Bielorussia 1
CO - Colombia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HT - Haiti 1
IS - Islanda 1
KR - Corea 1
MT - Malta 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SV - El Salvador 1
TH - Thailandia 1
TR - Turchia 1
UY - Uruguay 1
YT - Mayotte 1
ZW - Zimbabwe 1
Totale 6.669
Salva come PNG Salva come JPEG
Città #
Genoa 2.559
Genova 1.276
Vado Ligure 614
Rapallo 383
San Jose 196
Singapore 163
Ashburn 119
Ho Chi Minh City 68
Beijing 59
Hanoi 40
Lauterbourg 38
Hong Kong 26
Council Bluffs 24
New York 20
Boardman 16
Frankfurt am Main 14
Santa Clara 14
Milan 13
Buffalo 11
Los Angeles 11
St Louis 11
Bordighera 10
Chicago 10
Haiphong 10
Helsinki 10
Rome 10
Montreal 9
Mexico City 8
Ninh Bình 5
Rio de Janeiro 5
Tokyo 5
Toronto 5
Baku 4
Biên Hòa 4
Cardiff 4
Naples 4
Thái Nguyên 4
Tianjin 4
Trento 4
Zurich 4
Atlanta 3
Baghdad 3
Changsha 3
City of London 3
Dublin 3
Madrid 3
Orem 3
Riyadh 3
Rudolfstetten 3
São Paulo 3
Warsaw 3
Almaty 2
Amman 2
Aurora 2
Bologna 2
Brescia 2
Bình Phước 2
Charlotte 2
Columbus 2
Da Nang 2
Dallas 2
Erbil 2
Guangzhou 2
Jeddah 2
Johannesburg 2
Karachi 2
Kyiv 2
Memphis 2
Mumbai 2
Nairobi 2
New Delhi 2
Nuremberg 2
Paris 2
Parma 2
Phủ Lý 2
Porto Alegre 2
Quilmes 2
Quito 2
Quảng Ngãi 2
Quận Ba 2
Quận Bình Thạnh 2
San Antonio 2
San Francisco 2
Santiago 2
Seattle 2
Tampa 2
Tashkent 2
Vĩnh Long 2
Zagreb 2
Abbeville 1
Acalanes Ridge 1
Agadir 1
Alezio 1
Altamira 1
Americana 1
Amsterdam 1
Anchorage 1
Ankara 1
Anyang 1
Araruna 1
Totale 5.914
Salva come PNG Salva come JPEG
Nome #
Different MRI patterns in MS worsening after stopping fingolimod 204
Osteopathic Manipulative Therapy and Multiple Sclerosis: A Proof-of-Concept Study 202
123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies 189
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 183
Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers 180
"Limbic encephalitis with acute onset and Hu antibodies treated with rituximab: Paraneoplastic or non-paraneoplastic disorder?" 169
Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of “black holes” 160
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population 151
How much do periventricular lesions assist in distinguishing migraine with aura from CIS? 150
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 149
Could arterial spin labelling perfusion imaging uncover the invisible in N-methyl-d-aspartate receptor encephalitis? 147
A longitudinal clinical and MRI evaluation of the treatment with erenumab 144
Embracing resilience in multiple sclerosis: a new perspective from COVID-19 pandemic 140
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 138
Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma 135
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 135
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 127
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 126
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 123
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 123
Assessing upper limb function in Multiple Sclerosis by an engineered glove 123
Central vein sign and diffusion MRI differentiate microstructural features within white matter lesions of multiple sclerosis patients with comorbidities 121
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 119
Neuroimaging Findings in Mild Cognitive Impairment 118
Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study 118
Clinical and radiological correlates of apathy in multiple sclerosis 117
Effects of aging on finger movements in multiple sclerosis 117
Cognitive changes in patients with relapse-free MS treated with high efficacy therapies: the predictive value of paramagnetic rim lesions 114
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 113
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 110
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 109
In-vivo characterization of macro- and microstructural injury of the subventricular zone in relapsing-remitting and progressive multiple sclerosis 106
Sex differences in neuroimaging biomarkers in healthy subjects and dementia 102
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis 100
ADVANCED SUSCEPTIBILITY AND DIFFUSION WEIGHTED IMAGING IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS: FROM RESEARCH TO CLINICAL APPLICATIONS 100
Two-way crossed cerebellar diaschisis in a clinically isolated syndrome suggestive of multiple sclerosis 99
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 97
Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study 95
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series 94
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 92
A real-world study of alemtuzumab in a cohort of Italian patients 91
Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis 90
Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study 89
The effect of Cladribine and Fingolimod treatments on retinal atrophy 88
Improved detection of multiple sclerosis lesions with T2-prepared double inversion recovery at 3T 79
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis 78
Mapping tissue microstructure across the human brain on a clinical scanner with soma and neurite density image metrics 77
Brain lesion microstructure in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein disease 76
Lesion phenotyping based on magnetic susceptibility in pediatric multiple sclerosis 74
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 74
Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia 68
The role of disconnection in explaining disability in multiple sclerosis 68
Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature 67
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient 66
Multiparametric Characterization and Spatial Distribution of Different MS Lesion Phenotypes 63
A real-world study of Alemtuzumab in a cohort of Italian patients 61
Vaccinations in patients with multiple sclerosis: a real-world, single-center experience 53
Vaccinations in patients with multiple sclerosis: a real-world, single-center, experience 48
Effect of SARS-CoV-2 mRNA vaccination in multiple sclerosis patients treated with disease modifying therapies 47
Coagulation activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis 46
null 41
The “central vein sign” to differentiate multiple sclerosis frommigraine 39
Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis 38
Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection 35
Machine Learning Analysis Applied to Prediction of Early Progression Independent of Relapse Activity in Multiple Sclerosis Patients 23
null 20
E200k familial creutzfeldt-jakob disease presenting with subacute multiple cranial neuropathy 13
Totale 6.851
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.104
article - articoli 24.807
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 930
Totale 51.841
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 0 0 12
2021/2022339 21 4 12 28 21 30 12 72 27 43 19 50
2022/2023480 43 50 10 47 50 68 7 29 66 14 74 22
2023/2024626 24 42 18 76 35 83 122 37 30 18 36 105
2024/20251.714 105 113 72 90 196 153 155 307 97 97 187 142
2025/20262.667 393 72 199 237 342 156 361 146 235 295 145 86
Totale 6.851